November 25, 2016 - By Peter Erickson
Kepler Cheuvreux upgraded shares of STADA Arzneimittel (ETR:SAZ) to a “Buy” rating in a a research note issued to clients on 25 November. The firm currently has a EUR 55.00 target price on the stock. Kepler Cheuvreux’s target price suggests a potential upside of 28.84% from the stock’s last close price.
Out of 14 analysts covering STADA Arzneimittel (ETR:SAZ), 5 rate it a “Buy”, 2 “Sell”, while 7 “Hold”. This means 36% are positive. €55 is the highest target while €29 is the lowest. The €44.96 average target is 4.75% above today’s (€42.92) stock price. STADA Arzneimittel has been the topic of 80 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Jefferies maintained STADA Arzneimittel AG (ETR:SAZ) on Saturday, September 26 with “Hold” rating. The firm has “Buy” rating by Deutsche Bank given on Tuesday, December 1. The stock has “Hold” rating given by Landesbank on Wednesday, August 10. The firm earned “Hold” rating on Tuesday, December 8 by Independent Research. The rating was maintained by Warburg Research on Tuesday, June 7 with “Hold”. The rating was maintained by Warburg Research with “Hold” on Monday, January 4. The firm has “Buy” rating given on Wednesday, March 2 by Kepler Cheuvreux. The firm has “Hold” rating given on Thursday, March 3 by Independent Research. Jefferies maintained the stock with “Hold” rating in Thursday, March 24 report. The rating was maintained by DZ-Bank AG on Tuesday, June 7 with “Hold”.
About 26,956 shares traded hands. STADA Arzneimittel AG (ETR:SAZ) has risen 47.28% since April 28, 2016 and is uptrending. It has outperformed by 41.87% the S&P500.
Stada Arzneimittel AG is a Germany-based holding firm active in the pharmaceutical sector and healthcare market. The company has a market cap of 2.68 billion EUR. The Firm develops and markets products with off-patent active pharmaceutical ingredients. It has a 22.13 P/E ratio. The Company’s primary business divisions are Generics and Branded Products.
More notable recent STADA Arzneimittel AG (ETR:SAZ) news were published by: Wsj.com which released: “Stada Arzneimittel Holds Buyout Talks With CVC Capital” on May 25, 2016, also Wsj.com with their article: “Activist Investor to Pressure Stada AG to Explore Potential Sale” published on May 02, 2016, Wsj.com published: “Stada Arzneimittel Management Braced for Battle With Activist Investors” on August 15, 2016. More interesting news about STADA Arzneimittel AG (ETR:SAZ) were released by: Wsj.com and their article: “Stada Arzneimittel Chairman Departs After Marathon Shareholder Meeting” published on August 27, 2016 as well as Wsj.com‘s news article titled: “Stada Arzneimittel Feels More Heat From a Shareholder, Active Ownership” with publication date: July 25, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.